Oncotelic Therapeutics, Inc.

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows S-1/A and confirms the priced prospectus.

2025-12-23 · 0001493152-25-029081

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

2025-12-23 · 9999999995-25-003907

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

2025-12-22 · 0001493152-25-028813

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B3 in the pre-IPO sequence.

2025-11-21 · 0001493152-25-024676

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

2025-04-29 · 0001641172-25-006597

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

2025-04-21 · 9999999995-25-001157

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

2024-04-26 · 0001493152-24-016079

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

2024-04-22 · 9999999995-24-001057

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

2023-05-02 · 0001493152-23-015203

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

2023-04-25 · 9999999995-23-001036

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

2022-05-11 · 0001493152-22-012875

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

2022-05-06 · 9999999995-22-001341

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

2021-09-27 · 0001493152-21-023642

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

2021-09-09 · 9999999995-21-003459

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

2021-06-03 · 0001493152-21-013515

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

2021-06-02 · 9999999995-21-002188

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B5 in the pre-IPO sequence.

2021-05-24 · 0001493152-21-012757

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

2018-06-27 · 0001193125-18-204710

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

2018-06-26 · 9999999995-18-001626

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows RW in the pre-IPO sequence.

2018-06-13 · 0001193125-18-191628

RW withdrawn

Withdrawal request

Issuer requested withdrawal of the registration statement.

Follows S-1/A and ends the active registration process.

2018-05-18 · 0001193125-18-168003

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

2017-11-16 · 0001193125-17-345484

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior FWP filing.

2017-09-29 · 0001193125-17-299602

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows S-1/A and supplements the active offering with updated prospectus details.

2017-09-11 · 0001193125-17-281241

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior FWP filing.

2017-08-02 · 0001193125-17-245875

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows S-1/A and supplements the active offering with updated prospectus details.

2017-06-19 · 0001193125-17-206416

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

2017-06-13 · 0001193125-17-202010

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

2017-05-11 · 0001193125-17-167444

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

2015-06-05 · 9999999995-15-001547

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

2015-03-20 · 0001193125-15-100389

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

2014-06-16 · 0001193125-14-237795

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

2014-06-16 · 9999999995-14-001792

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B4 and confirms the priced prospectus.

2014-05-27 · 0001193125-14-212191

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

2014-02-13 · 0001193125-14-051057

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

2014-02-11 · 9999999995-14-000391

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior FWP filing.

2014-02-10 · 0001193125-14-042237

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows S-1/A and supplements the active offering with updated prospectus details.

2014-02-03 · 0001193125-14-033082

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

2014-01-31 · 0001193125-14-031037

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior 424B3 filing.

2014-01-24 · 0001193125-14-020577

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

2013-11-14 · 0001193125-13-442137

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows FWP and marks the registration effective.

2013-11-13 · 9999999995-13-003267

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows S-1/A and supplements the active offering with updated prospectus details.

2013-09-09 · 0001193125-13-360875

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

2013-08-29 · 0001193125-13-352276

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B3 in the pre-IPO sequence.

2013-08-08 · 0001193125-13-324995

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

2013-05-02 · 0001193125-13-194303

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

2013-05-01 · 9999999995-13-001363

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

2013-02-22 · 0001193125-13-070440

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

2012-11-27 · 0001193125-12-481679

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

2012-09-05 · 0001193125-12-380923

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

2012-09-05 · 0001193125-12-381233

424B2 filed

Prospectus supplement

Prospectus supplement that can carry timing details without itself confirming imminent trading.

Follows 424B3 in the pre-IPO sequence.

2012-06-14 · 0001193125-12-271034

424B2 filed

Prospectus supplement

Prospectus supplement that can carry timing details without itself confirming imminent trading.

Follows 424B2 in the pre-IPO sequence.

2012-06-14 · 0001193125-12-271041

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B2 and marks the registration effective.

2012-06-14 · 9999999995-12-001840

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

2012-06-08 · 0001193125-12-265215

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

2012-04-18 · 0001193125-12-167436

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

2012-04-18 · 9999999995-12-001090

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

2012-01-12 · 0000950123-12-000683

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

2012-01-11 · 9999999995-12-000163

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B5 in the pre-IPO sequence.

2011-12-22 · 0000950123-11-103800

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

2011-07-08 · 0000950123-11-064689

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

2011-06-29 · 0000950123-11-062657

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

2011-06-08 · 9999999995-11-001768

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

2011-06-01 · 0000950123-11-055799

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

2011-01-31 · 0000950123-11-007346

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

2010-09-23 · 0000950123-10-088418

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

2010-08-17 · 0000950123-10-078323

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

2010-07-22 · 0000950123-10-066973

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

2010-06-16 · 9999999995-10-001841

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

2010-06-10 · 0000950123-10-057311

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

2010-04-29 · 0000950123-10-040710

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

2010-04-29 · 9999999995-10-001235

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

2009-12-23 · 0000950123-09-072852

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

2009-12-21 · 9999999995-09-003577

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 425 and confirms the priced prospectus.

2009-12-09 · 0000950123-09-069595

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows S-4 in the pre-IPO sequence.

2009-12-03 · 0000950123-09-068053

S-4 filed

S-4

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2009-11-30 · 0000950123-09-066957

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2009-11-20 · 0000950123-09-064675

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2009-11-17 · 0000950123-09-063495

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2009-11-10 · 0000950123-09-060748

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2009-11-09 · 0000950123-09-059969

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2009-11-09 · 0000950123-09-060342

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2009-10-16 · 0000950123-09-051017

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows EFFECT in the pre-IPO sequence.

2009-10-15 · 0000950123-09-050563

425 supplemental

425

Pre-IPO filing captured from the SEC submission timeline.

Follows 425 in the pre-IPO sequence.

2009-10-15 · 0000950123-09-050694

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

2009-08-25 · 9999999995-09-002379

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

10,000,000 shares · Gross proceeds $0.00

Common Stock · Exchange NASDAQ · Ticker OXGN · Selling stockholders only · Use of proceeds Proceeds will go to the selling stockholder, not the company

Oncotelic Therapeutics, Inc. (now OXiGENE, Inc.) filed a 424B3 prospectus for the resale of 10 million common shares by Symphony ViDA Holdings LLC, a selling stockholder. The shares were issued under an Amended Purchase Option Agreement, and the company will not receive proceeds from the resale. The filing outlines the plan of distribution, notes the stock's NASDAQ listing, and highlights risks associated with clinical trials for ZYBRESTAT, a vascular disrupting agent (VDA) in development for cancer and ophthalmological indications.

2009-08-14 · 0000950123-09-035239

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

The filing confirms the effectiveness of Oncotelic Therapeutics, Inc.'s (formerly OXIGENE, INC.) S-3 registration statement for an offering of up to 6,250,000 shares of common stock and warrants to purchase 5,625,000 shares. The offering includes units comprising one share, two warrants (Series I and II), and is priced at $1.60 per unit. Lazard Capital Markets LLC and Merriman Curhan Ford & Co. act as placement agents. Proceeds are estimated at $9.35 million before expenses, with funds held in escrow until the offering closes.

2009-08-13 · 9999999995-09-002270

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

Shares of common stock and warrants to purchase common stock · Exchange NASDAQ · Ticker OXGN · Each unit consists of one share of common stock, a five-year warrant to purchase [ ] of a share of common stock, and a short-term warrant to purchase [ ] of a share of common stock · Warrants to purchase common stock with two exercise prices · Use of proceeds Proceeds will be used for working capital · Underwriters Lazard Capital Markets LLC, Merriman Curhan Ford & Co.

Oncotelic Therapeutics, Inc. (formerly OXIGENE, Inc.) is conducting a follow-up offering of up to [ ] shares of common stock and warrants to purchase [ ] shares, structured in units with specific exercise prices and terms. This follows a prior 424B3 filing focused on resale by a selling stockholder. The offering involves placement agents Lazard Capital Markets LLC and Merriman Curhan Ford & Co., with proceeds intended for general corporate purposes. The company remains a clinical-stage biopharmaceutical firm developing vascular disrupting agents (VDAs) for cancer and ophthalmological indications.

2009-07-15 · 0000950123-09-022314

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $1.60 · 6,250,000 shares · Gross proceeds $10,000,000

Common Stock · Exchange NASDAQ · Ticker OXGN · Each unit consists of one share of common stock, a five-year warrant to purchase 0.45 shares, and a short-term warrant to purchase 0.45 shares · Series I and II warrants to purchase 2,812,500 shares each at $2.10 and $1.60 exercise prices · Use of proceeds working capital · Flags units, warrants, best_efforts · Underwriters Lazard Capital Markets LLC, Merriman Curhan Ford & Co.

Oncotelic Therapeutics, Inc. is offering up to 6,250,000 shares of common stock and warrants to purchase 5,625,000 shares of common stock in a registered direct offering. The securities are sold in units comprising one share of common stock, two warrants (five-year and short-term), at a negotiated price of $1.60 per unit. The offering is being conducted by Lazard Capital Markets LLC (lead placement agent) and Merriman Curhan Ford & Co. (co-placement agent), with expected closing on July 20, 2009. Proceeds, before expenses, are estimated at $9.35 million.

2009-07-15 · 0000950123-09-022398

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

17,117,118 shares · Gross proceeds $0.00

Common Stock · Exchange NASDAQ · Ticker OXGN · Selling stockholders only · Use of proceeds Proceeds will go to the selling stockholder, no issuer proceeds

Oncotelic Therapeutics, Inc. (formerly OXiGENE, Inc.) is a clinical-stage biopharmaceutical company focused on developing vascular disrupting agents (VDAs) for cancer and eye diseases. The current 424B3 filing relates to the resale of up to 17,117,118 shares of common stock by Symphony ViDA Holdings LLC, including 5,835,241 issued shares and 11,281,877 shares from a warrant. The company is not receiving proceeds from the offering, which is part of a broader licensing and development agreement with Symphony ViDA, Inc., involving ZYBRESTAT and OXi4503. Key clinical programs include Phase II/III trials for anaplastic thyroid cancer and Phase I trials for OXi4503 in acute myeloid leukemia.

2008-12-02 · 0000950135-08-007690

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

The Notice of Effectiveness confirms the activation of OXIGENE, Inc.'s Form S-3 registration statement, permitting the resale of 5,958,035 shares of common stock by Kingsbridge Capital Limited. The filing incorporates the company's Quarterly Report on Form 10-Q for the period ended September 30, 2008, and emphasizes that the company will not receive proceeds from the resale. The document reiterates risks associated with the company's clinical-stage operations, financial losses, and dependence on external partners.

2008-12-01 · 9999999995-08-003547

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

The filing confirms the effectiveness of Oncotelic Therapeutics, Inc.'s S-3 registration statement on December 1, 2008. The document relates to a securities offering, though specific details about the offering's scope, pricing, or purpose are not included in the provided text. The filing appears to be a standard Notice of Effectiveness for an SEC registration statement.

2008-12-01 · 9999999995-08-003548

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

5,958,035 shares · Gross proceeds $0.00

Common Stock · Selling stockholders only · Use of proceeds Proceeds will go to the selling stockholders, with no proceeds to the company

The current filing is a prospectus supplement for OXiGENE, Inc., updating the registration statement for the resale of 5,958,035 shares of common stock by Kingsbridge Capital Limited. It includes the company's quarterly financial results for the period ending September 30, 2008, highlighting continued losses, negative cash flow, and reliance on external financing. The filing emphasizes risks related to clinical trial outcomes, regulatory approval, and insufficient capital to sustain operations.

2008-11-07 · 0000950135-08-007051

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

5,958,035 shares · Gross proceeds $0.00

Common Stock · Ticker OXIGENE · Selling stockholders only · Use of proceeds Proceeds will be used by selling stockholders, with no proceeds to the company

Oncotelic Therapeutics, Inc. (formerly OXiGENE, Inc.) filed a prospectus supplement (424B3) to update its registration statement for the resale of 5,958,035 shares of common stock by Kingsbridge Capital Limited. The filing includes a quarterly report (10-Q) for the period ended June 30, 2008, and emphasizes risks associated with the company's clinical-stage operations, including dependence on clinical trials, regulatory approvals, and insufficient capital. The company highlighted ongoing development of vascular disrupting agents (VDAs) like ZYBRESTAT for cancer and ocular diseases.

2008-08-08 · 0000950135-08-005473

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

5,958,035 shares · Gross proceeds $0.00

Common Stock · Exchange NASDAQ Global Market · Ticker OXGN · Warrant to purchase 250,000 shares of common stock · Selling stockholders only · Use of proceeds Proceeds will not be received by the company; the selling stockholder will receive all proceeds

The 424B3 filing supplements the prospectus for OXiGENE, Inc. to reflect a drawdown under a common stock purchase agreement with Kingsbridge Capital Limited. It details the issuance of 634,600 shares at $900,000, priced at a 12% discount to NASDAQ prices. The filing emphasizes risks associated with clinical-stage biopharmaceutical development, including reliance on ZYBRESTAT and other VDA candidates, regulatory uncertainties, and market volatility.

2008-06-09 · 0000950135-08-004263

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

OXIGENE, Inc. filed an S-1 registration statement for the resale of up to 5,958,035 shares of common stock by a selling stockholder, Kingsbridge Capital Limited. The offering includes shares from a February 2008 purchase agreement and warrants. The company is a clinical-stage biopharmaceutical firm focused on vascular disrupting agents (VDAs) for cancer and eye diseases. The filing includes a preliminary prospectus with risk factors, a plan of distribution, and financial disclosures. The registration became effective on May 15, 2008.

2008-05-15 · 9999999995-08-001603

RW withdrawn

Withdrawal request

Issuer requested withdrawal of the registration statement.

Follows 424B5 and ends the active registration process.

Oncotelic Therapeutics, Inc. (formerly OXiGENE, Inc.) filed a request to withdraw its previously submitted Registration Statement on Form S-3 (File No. 333-149787) with the SEC. The withdrawal follows the company's decision to refile a Registration Statement on Form S-1 to address SEC staff comments. The original S-3 filing, made on March 18, 2008, had not been declared effective, and no securities were issued under it. The company seeks to credit fees paid for the S-3 filing toward its upcoming S-1 registration.

2008-05-02 · 0000950135-08-003300

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows RW in the pre-IPO sequence.

Price $1.62 · Range $1.62 to $2.74 · 5,958,035 shares · Gross proceeds $9,932,017

Common Stock, $0.01 par value per share · Exchange NASDAQ Global Market · Ticker OXGN · Warrants to purchase 250,000 shares at $2.74 per share · Selling stockholders only · Use of proceeds selling stockholders with no issuer proceeds · Flags warrants

OXiGENE, Inc. is a clinical-stage biopharmaceutical company focused on developing vascular disrupting agents (VDAs) for cancer and eye diseases. The company is registering 5,958,035 shares of common stock for resale by a selling stockholder, including shares from a warrant. Its lead candidate, ZYBRESTAT, is in Phase II/III trials for anaplastic thyroid cancer and other solid tumors, with additional programs in ophthalmology and a second-generation VDA, OXi4503, in Phase I trials. The filing replaces a previously withdrawn S-3 registration due to SEC feedback.

2008-05-02 · 0000950135-08-003302

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $3.65 · 6,500,000 shares · Gross proceeds $22,182,550

Common · Exchange NASDAQ · Ticker OXGN · Over-allotment 975,000 · Use of proceeds for general corporate purposes · Underwriters SG Cowen & Co., Lazard Capital Markets

Oncotelic Therapeutics, Inc. (formerly OXiGENE, Inc.) is offering 6,500,000 shares of common stock at $3.65 per share, with underwriters covering potential over-allotments. The company focuses on developing vascular disrupting agents (VDAs) like CA4P for cancer and ophthalmic treatments. Key clinical trials include a Phase III trial for non-small cell lung cancer and Phase II trials for ovarian, cervical, and colorectal cancers, as well as ophthalmic indications. The filing emphasizes risks related to clinical trial outcomes, regulatory approvals, and reliance on CA4P.

2005-12-15 · 0000950135-05-006974

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

First tracked pre-IPO filing for this issuer.

6,000,000 shares

Common Stock · Exchange Nasdaq National Market · Ticker OXGN · Over-allotment 900,000 · Underwriters SG Cowen & Co., Lazard Capital Markets

OXiGENE, Inc. is offering 6,000,000 shares of common stock, with its lead candidate CA4P in multiple clinical trials for oncology and ophthalmology indications. The company focuses on vascular disrupting agents (VDAs) and ortho-quinone prodrugs (OQPs) for cancer and eye diseases, with recent preclinical data suggesting enhanced efficacy when combined with anti-angiogenic therapies like Avastin. The offering is part of a shelf registration allowing up to $75M in securities.

2005-12-01 · 0000950135-05-006746

Oncotelic Therapeutics, Inc.

Filing Timeline

10 comparable deals

Recent News